SRC and cancer: Given its excellent physicochemical properties and promising in vitro DMPK profile, 72 was further evaluated in cancer models and in vivo (zebrafish and mice).113 Mirroring the activity of ABL/nonSRC inhibitor imatinib, 72 is the only in vivo active SRC inhibitor with selectivity over ABL.